These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 10598340

  • 21. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A, Okamura T.
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
    [Abstract] [Full Text] [Related]

  • 22. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
    Garver DL, Holcomb JA, Christensen JD.
    Biol Psychiatry; 2005 Jul 01; 58(1):62-6. PubMed ID: 15992524
    [Abstract] [Full Text] [Related]

  • 23. Atypical antipsychotic drugs improve cognition in schizophrenia.
    Meltzer HY, Sumiyoshi T.
    Biol Psychiatry; 2003 Feb 01; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
    [No Abstract] [Full Text] [Related]

  • 24. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine.
    Classen W, Laux G.
    Pharmacopsychiatry; 1988 Nov 01; 21(6):295-7. PubMed ID: 2907629
    [No Abstract] [Full Text] [Related]

  • 25. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
    Williams LM, Loughland CM, Green MJ, Harris AW, Gordon E.
    Psychiatry Res; 2003 Aug 30; 120(1):13-27. PubMed ID: 14500110
    [Abstract] [Full Text] [Related]

  • 26. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
    Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC.
    Int Clin Psychopharmacol; 2001 Nov 30; 16(6):325-30. PubMed ID: 11712620
    [Abstract] [Full Text] [Related]

  • 27. Akathisia and suicidal ideation in first-episode schizophrenia.
    Seemüller F, Schennach R, Mayr A, Musil R, Jäger M, Maier W, Klingenberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Möller HJ, Riedel M, German Study Group on First-Episode Schizophrenia.
    J Clin Psychopharmacol; 2012 Oct 30; 32(5):694-8. PubMed ID: 22926606
    [Abstract] [Full Text] [Related]

  • 28. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
    Blin O, Azorin JM, Bouhours P.
    J Clin Psychopharmacol; 1996 Feb 30; 16(1):38-44. PubMed ID: 8834417
    [Abstract] [Full Text] [Related]

  • 29. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.
    McGurk SR, Green MF, Wirshing WC, Wirshing DA, Marder SR, Mintz J, Kern R.
    Schizophr Res; 2004 Jun 01; 68(2-3):225-33. PubMed ID: 15099605
    [Abstract] [Full Text] [Related]

  • 30. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety.
    Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I.
    Clin Ther; 1998 Jun 01; 20(1):58-71. PubMed ID: 9522104
    [Abstract] [Full Text] [Related]

  • 31. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
    Kagerer S, Winter C, Möller HJ, Soyka M.
    Neuropsychobiology; 2003 Jun 01; 47(4):212-8. PubMed ID: 12824745
    [Abstract] [Full Text] [Related]

  • 32. Driving ability under sertindole.
    Brunnauer A, Laux G.
    Pharmacopsychiatry; 2012 Mar 01; 45(2):47-50. PubMed ID: 21989603
    [Abstract] [Full Text] [Related]

  • 33. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
    Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Gaebel W, Seemüller F, Möller HJ, Riedel M.
    Eur Neuropsychopharmacol; 2011 May 01; 21(5):370-8. PubMed ID: 21255982
    [Abstract] [Full Text] [Related]

  • 34. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics.
    Kumari V, Soni W, Sharma T.
    Schizophr Res; 2002 May 01; 55(1-2):139-46. PubMed ID: 11955973
    [Abstract] [Full Text] [Related]

  • 35. Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
    Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK, Kelly DL, Conley RR.
    J Clin Psychopharmacol; 2007 Aug 01; 27(4):400-1. PubMed ID: 17632229
    [No Abstract] [Full Text] [Related]

  • 36. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol.
    Classen W, Laux G.
    Neuropsychobiology; 1989 Aug 01; 21(3):131-40. PubMed ID: 2575719
    [Abstract] [Full Text] [Related]

  • 37. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
    Meibach RC.
    Neurology; 2000 Oct 10; 55(7):1069. PubMed ID: 11061283
    [No Abstract] [Full Text] [Related]

  • 38. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
    Addington J, Addington D.
    Can J Psychiatry; 1997 Nov 10; 42(9):983. PubMed ID: 9429073
    [No Abstract] [Full Text] [Related]

  • 39. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E, Lussier I.
    Can J Psychiatry; 1996 Oct 10; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [Abstract] [Full Text] [Related]

  • 40. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
    Chouinard G, Albright PS.
    J Clin Psychopharmacol; 1997 Aug 10; 17(4):298-307. PubMed ID: 9241010
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.